US panel to consider Lilly's Cymbalta for chronic pain
This article was originally published in Scrip
Executive Summary
The proposed use of Lilly's antidepressant Cymbalta (duloxetine) for management of chronic pain will be reviewed by the US FDA's anaesthetic and life support drugs advisory panel on January 28th.